Amgen Inc.
267.00
-3.19 (-1.18%)
At close: Jan 14, 2025, 3:59 PM
267.65
0.24%
After-hours Jan 14, 2025, 06:53 PM EST
undefined%
Bid 265.01
Market Cap 143.52B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 7.84
PE Ratio (ttm) 34.06
Forward PE n/a
Analyst Hold
Ask 267.99
Volume 1,996,433
Avg. Volume (20D) 3,444,575
Open 271.61
Previous Close 270.19
Day's Range 264.91 - 271.61
52-Week Range 253.30 - 346.85
Beta undefined

About AMGN

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopaus...

Sector Healthcare
IPO Date Jun 17, 1983
Employees 26,700
Stock Exchange NASDAQ
Ticker Symbol AMGN

Analyst Forecast

According to 23 analyst ratings, the average rating for AMGN stock is "Hold." The 12-month stock price forecast is $328, which is an increase of 22.85% from the latest price.

Buy 47.83%
Hold 39.13%
Sell 8.70%
Stock Forecasts

Next Earnings Release

Amgen Inc. is scheduled to release its earnings on Feb 4, 2025, after market closes.
Analysts project revenue of $8.85B, reflecting a 7.98% YoY growth and earnings per share of 5.03, making a 6.79% increase YoY.
1 month ago · Source
-4.76%
Amgen shares are trading lower following the resul... Unlock content with Pro Subscription
2 months ago · Source
-4.16%
Shares of pharmaceutical and healthcare stocks are trading lower. The sector has been under pressure after president-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS.